165947-52-4

Usage

Uses

Used in Pharmaceutical Industry:
6-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-6H-thieno[2,3-c]pyridine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of new drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 6-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-6H-thieno[2,3-c]pyridine is utilized as a building block for the development of novel agrochemical products. Its structural properties contribute to the formulation of new pesticides or herbicides with improved efficacy and reduced environmental impact.
Used in Material Science:
6-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-6H-thieno[2,3-c]pyridine is employed as a key component in the synthesis of advanced materials. Its incorporation into material compositions can lead to the development of new materials with enhanced properties, such as improved conductivity, strength, or stability, for use in various applications.

InChI:InChI=1/C12H17NO2S/c1-12(2,3)15-11(14)13-6-4-9-5-7-16-10(9)8-13/h5,7H,4,6,8H2,1-3H3

Upstream product

• 179061-06-4 N-tert-butoxycarbonyl-2-(3-thienyl)ethylamine 
• 50-00-0 formaldehyd 
• 24424-99-5 di-tert-butyl dicarbonate 
• 28783-38-2 4,5,6,7-tetrahydrothieno[2,3-c]pyridine hydrochloride 
• 59311-67-0 2-(3-thienyl)ethylamine 
• 28783-48-4 N-(2-(thiophen-3-yl)ethyl)formamide 
• 28783-50-8 3,4-dihydrothieno<2,3-c>pyridine 
• 62019-71-0 4,5,6,7-tetrahydro-thieno[2,3-c]pyridine 
• 13781-53-8 (thiophen-3-yl)acetonitrile 

Downstream Products

• 203663-30-3 tert-butyl 2-formyl-4,5-dihydrothieno[2,3-c]pyridine-6(7H)-carboxylate 
• 28783-38-2 4,5,6,7-tetrahydrothieno[2,3-c]pyridine hydrochloride 
• 1423033-44-6 2-bromo-4,5,6,7-tetrahydrothieno[2,3-c]pyridine hydrobromide 
• 1575610-02-4 (2R, 3R)-3-(2-bromo-4, 5-dihydrothieno[2, 3-c]pyridin-6(7H)-yl)-2-(2, 4-difluorophenyl)-1-(1H-1, 2, 4-triazol-1-yl)butan-2-ol 
• 1575610-03-5 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyridin-4-yl)-4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575610-07-9 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyridin-3-yl)-4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575610-09-1 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(pyrimidin-5-yl)-4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 1575610-12-6 (2R,3R)-2-(2,4-difluorophenyl)-3-(2-(2-cyanopyridin-5-yl)-4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 

Relevant academic research and scientific papers

Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy

KCNQ (Kv7) has emerged as a validated target for the development of novel anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives were designed, synthesized and evaluated as KCNQ openers for the treatment of epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro and in vivo. Several compounds were found to be potent KCNQ openers. Compound 1 with favorable in vitro activity was submitted to evaluation in vivo. Results showed that compound 1 owned significant anti-convulsant activity with no adverse effects. It was also found to posses favorable pharmacokinetic profiles in rat. This research may provide novel potent compounds for the discovery of KCNQ openers in treating epilepsy.

Substituted oxazolidinone compounds and method and use thereof

The invention provides a substituted oxazolidinone compound represented by a formula (I) shown in specifications, or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof. The compound i

Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility

Triazoles with fused-heterocycle nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SAR of antifungal triazoles. Tetrahydro-[1,2,4] triazolo[1,5-a]pyrazine and tetrahydro-thiazolo[5,4-c]pyridine nuclei were preferable to the other four fused-heterocycle nuclei investigated. Potent in vitro activity, broad spectrum and better water solubility were attained when triazoles containing nitrogen aromatic heterocycles were attached to these two nuclei. The most potent compounds 27aa and 45x, with low hERG inhibition and hepatocyte toxicity, both exhibited excellent activity against Candida, Cryptococcus, and Aspergillus spp., as well as selected fluconazole-resistant strains. A high water-soluble compound 58 (the disulfate salt of 45x) displayed unsatisfactory in vivo activity because of its poor PK profiles. Mice infected with C.alb. SC5314 and C.alb. 103 (fluconazole-resistant strain) and administered with 27aa displayed significantly improved survival rates. 27aa also showed favorable pharmacokinetic (PK) profiles.

Benzopiperidine derivatives

Benzopiperidine derivatives represented by formula (I), salts thereof or hydrates thereof, processes for producing the same and drugs comprising the same: wherein the variables are as described in the specification. These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and rejection reaction accompanying organ transplantation.

Condensed compounds, their production and use

This invention provides new condensed furan compounds which exhibit excellent 2,3-oxidosqualene cyclase inhibition and high-density lipoprotein-cholesterol elevating activities. This invention also provides a therapeutic and prophylactic agent for hyperlipidemia, hypercholesterolemia and atherosclerosis.